Mycotopia Therapies, Inc. (TPIA) Financial Statements (2024 and earlier)
Company Profile
Business Address |
480 22ND STREET HEYBURN, ID 83336 |
State of Incorp. | NV |
Fiscal Year End | December 31 |
Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
---|---|---|---|---|---|---|---|
ASSETS | |||||||
Current Assets | |||||||
Cash, cash equivalents, and short-term investments | 385,899 | 1,267,519 | 57,359 | 709,164 | |||
Cash and cash equivalents | 385,899 | 1,267,519 | 57,359 | 709,164 | |||
Receivables | 1,000 | ||||||
Prepaid expense | 7,606 | ||||||
Disposal group, including discontinued operation | 34,806 | 946,715 | |||||
Other current assets | 48,096 | 50,100 | |||||
Other undisclosed current assets | 315,194 | (500,000) | |||||
Total current assets: | 385,899 | 1,267,519 | 455,455 | 1,214,585 | |||
Noncurrent Assets | |||||||
Property, plant and equipment | 1,496 | 2,497 | 548 | ||||
Total noncurrent assets: | 1,496 | 2,497 | 548 | ||||
TOTAL ASSETS: | 387,395 | 1,270,016 | 455,455 | 1,215,133 | |||
LIABILITIES AND EQUITY | |||||||
Liabilities | |||||||
Current Liabilities | |||||||
Accounts payable and accrued liabilities, including: | 335,590 | 171,031 | 1,149 | 55,967 | |||
Accrued liabilities | 10,339 | 1,149 | 55,967 | ||||
Other undisclosed accounts payable and accrued liabilities | 335,590 | 160,692 | |||||
Debt | 140,923 | ||||||
Due to related parties | ✕ | 125,000 | |||||
Other liabilities | 507,263 | ||||||
Other undisclosed current liabilities | 288,000 | 10,339 | |||||
Total current liabilities: | 764,513 | 306,370 | 1,149 | 563,230 | |||
Noncurrent Liabilities | |||||||
Long-term debt and lease obligation | 514,230 | ||||||
Long-term debt, excluding current maturities | 514,230 | ||||||
Liabilities, other than long-term debt | 500,000 | ||||||
Due to related parties | ✕ | 500,000 | |||||
Other undisclosed noncurrent liabilities | 123,625 | ||||||
Total noncurrent liabilities: | 514,230 | 623,625 | |||||
Total liabilities: | 1,278,743 | 929,995 | 1,149 | 563,230 | |||
Equity | |||||||
Equity, attributable to parent | (891,348) | 340,021 | 454,306 | 651,903 | |||
Common stock | 14,857 | 13,966 | 12,925 | 12,425 | |||
Additional paid in capital | 6,873,429 | 3,175,959 | 70,354 | 26,246 | |||
Retained earnings (accumulated deficit) | (7,779,634) | (2,849,904) | 371,027 | 613,232 | |||
Total equity: | (891,348) | 340,021 | 454,306 | 651,903 | |||
TOTAL LIABILITIES AND EQUITY: | 387,395 | 1,270,016 | 455,455 | 1,215,133 |
Income Statement (P&L) (USD)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
---|---|---|---|---|---|---|
Operating expenses | (1,736,336) | (2,669,109) | (251,718) | |||
Operating loss: | (1,736,336) | (2,669,109) | (251,718) | |||
Nonoperating expense | (875,533) | (151,621) | (1,504) | |||
Investment income, nonoperating | 16,253 | |||||
Other nonoperating income | 22,251 | |||||
Interest and debt expense | (868,330) | (143,057) | (8) | |||
Loss from continuing operations before equity method investments, income taxes: | (3,480,199) | (2,963,787) | (253,230) | |||
Other undisclosed income from continuing operations before income taxes | 868,330 | 143,057 | 8 | |||
Loss from continuing operations: | (2,611,869) | (2,820,730) | (253,222) | |||
Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | (2,820,730) | 84,970 | (253,222) | |
Income from discontinued operations | 84,970 | |||||
Other undisclosed net income (loss) | (327,175) | 258,025 | ||||
Net income (loss) available to common stockholders, diluted: | (2,611,869) | (2,820,730) | (242,205) | 4,803 |
Comprehensive Income (USD)
9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
---|---|---|---|---|---|---|
Net income (loss): | (2,611,869) | (2,820,730) | (242,205) | 4,803 | ||
Comprehensive income (loss), net of tax, attributable to parent: | (2,611,869) | (2,820,730) | (242,205) | 4,803 |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.